CD19 and neoplasm: Notably, the transfer of UCB-T cells secreting IL-12 resulted in increased survival of CD19+ tumor-bearing mice (>40 days of survival vs <40 days of survival compared to controls; *P < 0.05) without a need for pretreatment (irradiation) or IL-2 support.